The market seems to be mispricing HCA Healthcare, Inc., as the stock traded above its DCF value, suggesting overvaluation. However, the Forward P/E of 8.60 and an impressive Earnings Yield of 7.02% indicate potential undervaluation relative to future earnings. The Altman Z-score of 2.73 suggests moderate financial health, not quite a fortress but stable enough to avoid immediate distress. Despite a negative Price/Book ratio, the company’s valuation metrics hint at a complex narrative where growth potential might be underestimated by the market. Investors should weigh these factors carefully, as the stock’s current pricing might not fully reflect its intrinsic value.